High tumor burden in non-small-cell lung cancer: A review of the literature.

J Clin Transl Res · 2022 · PMC9741935 · PMID 36518549

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A pooled analysis of the Checkmate 017, 057, and 063 trials of nivolumab versus docetaxel in second-line treatment of NSCLC showed a trend toward improved OS in favor of nivolumab in patients with pre-treated CNS metastases (8.4 vs. 6.2 months).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.